Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81
Hepatitis C virus (HCV) infects 3% of world population being responsible for nearly half a million deaths annually urging the need for a prophylactic vaccine. Retrovirus like particles are commonly used scaffolds for antigens presentation being the core of diverse vaccine candidates. The immunogenicity of host proteins naturally incorporated in retrovirus was hypothesized to impact the performance of retrovirus based vaccines. In this work, the capacity of engineered retrovirus like particles devoided of host protein CD81 to display HCV envelope antigens was compared to non-engineered particles. A persistent inability of CD81 negative VLPs to incorporate HCV E2 protein as a result from the inefficient transport of HCV E2 to the plasma membrane, was observed. This work enabled the identification of a CD81-mediated transport of HCV E2 while stressing the importance of host proteins for the development of recombinant vaccines.
KeywordsHCV CD81 Retrovirus E2 E1 Transport
With no licensed prophylactic vaccine, Hepatitis C virus (HCV) is considered one of the most important human pathogens of the XXI century, infecting approximately 80 million people worldwide (Baumert et al. 2014; Gower et al. 2014). The high genetic diversity of HCV genotypes, the extended capacity of HCV to circumvent immune defenses and the absence of suitable animal models to evaluate vaccine efficacy are major challenges for HCV vaccine development (Bellier and Klatzmann 2013). Additionally, the risk of an asymptomatic HCV infection associated to vaccine reversion limits the use of classical inactivated and live-attenuated vaccine candidates.
As a result, HCV vaccine candidates undergoing pre-clinical and clinical evaluation use non-conventional antigens such as vectored vaccines, recombinant protein cocktails and virus-like particles (VLPs) (Garrone et al. 2011; Huret et al. 2013). The latter have shown to be potent vaccine antigens as a result from their particulate nature even in the absence of adjuvants (Bellier et al. 2006, 2009; Gogesch et al. 2018). Virus-like particles based in Murine Leukemia virus (MLV) are the core of diverse vaccine candidates against pathogens such as Cytomegalovirus, West Nile fever virus, Hepatitis C virus and human immunodeficiency virus due to their capacity to incorporate high amounts of foreign membrane proteins (Bellier et al. 2006, 2009; Desjardins et al. 2009; Kirchmeier et al. 2014; Pitoiset et al. 2017). Murine Leukemia virus acquires its lipid envelope by extracting a fragment of the plasma membrane during budding stage which results in the incorporation of host membrane proteins in fully assembled particles (Segura et al. 2008; Soares et al. 2016). We have previously shown that host proteins incorporated in MLV-based VLPs, or retroVLPs, such as the tetraspanins CD81, CD63 and CD9, trigger the production of antibodies in mice thus conferring retroVLPs their basal immunogenity (Soares et al. 2016).
Similar to retrovirus, host proteins are known to associate with HCV virions (Lussignol et al. 2016). Even though the immunogenic profile of these host proteins is unknown, chronic HCV infections often result in the production of autoreactive antibodies (Roughan et al. 2012). Here we hypothesize the use of engineered retroVLPs with reduced CD81-specific immunogenicity to study the role of host proteins in HCV immunity and to support the development of engineered HCV vaccine candidates.
In this work CD81 positive and CD81 negative cells were used to produce retroVLPs pseudotyped with HCV envelope proteins. An inefficient transport of HCV E2 to the plasma membrane of CD81 silenced cells however hampered HCV pseudotyping of retroVLPs in these cells. The inefficient transport of HCV E2 was further confirmed in cells producing HCV-like particles. Contrasting with the prevalent hypothesis arguing for an inefficient retention of viral proteins in the endoplasmic reticulum (ER) (Bartosch et al. 2003; Op De Beeck et al. 2004) our results suggest the existence of a CD81-mediated transport of HCV E2 to the plasma membrane. Our results also show that the transport of HCV E1 is independent from HCV E2 and CD81 thus contributing for the development of E1-only vaccine candidates.
Materials and methods
Cell lines and culture media
293rVLP and 293rVLP-shCD81 cell lines derive from HEK 293 (ATCC CRL-1573) by stable expression of MLV gag-pro-pol gene for continuous production of recombinant retrovirus products (Rodrigues et al. 2011). 293rVLP-HCVpp and 293rVLP-HCVpp shCD81 (BEE) cells derived from the previous cells by stable transfection of pEPX145-71 plasmid expressing HCV E1 and E2 genes (Garrone et al. 2011) and pMonoZeoMCS, a plasmid containing the zeocin resistance gene in a ratio 1:20 (m/m), using 1 µg P.E.I. to 1.5 µg of DNA. 293rVLP-HCVpp shCD81 (AEE) cells derive from 293rVLP-HCVpp upon silencing endogenous CD81 expression. To establish HCV-LP producer cells, HuH-7 (JCRB 0403) and HEK 293 (ATCC CRL-1573) were used. All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco) at 37 °C inside an incubator with a humidified atmosphere of 5% CO2 in air. A summary table with all cell lines used and developed is available as Additional file 1: Table S1.
Cell transduction and selection
For the establishment of de novo CD81 silenced cell populations 293rVLP-HCVpp, 293-HCVCore-NS2 and HuH7-HCVCore-NS2 cells were seeded in six-well plates at 5 × 104 cells/cm2; 24 h later, culture medium was replaced by 600 µL of lentiviral supernatant containing shRNA#10, (Rodrigues et al. 2011) targeting CD81 supplemented with 8 mg/mL of Polybrene (Sigma-Aldrich). After 4 h incubation at 37 °C, 1.5 mL of DMEM 10% FBS (v/v) was added. 48 h post-infection, cells were expanded and cultured for 21 days in DMEM containing puromycin (1.5 mg/mL). For further enhancement of CD81 down-regulation, initial shCD81#10 cell populations were subsequently infected with shCD81 #9 and #12, as described previously (Rodrigues et al. 2011), followed by 14 days selection with 3 mg/mL puromycin, establishing the final shCD81 cell population. The development of 293-HCVCore-NS2, HuH-7-HCVCore-NS2 and corresponding shCD81 derived cells is summarized in Additional file 1: Figures S4 and S5 schematic representations.
Cell lysates were prepared by adding 100 µL of M-PER extraction buffer (Thermo Scientific, Waltham, MA, USA) per 1 × 106 cells. The total protein concentration in cell lysates or purified virus samples was determined using Pierce™ BCA Protein Assay Kit (Thermo Scientific). 15 µg of protein extracts or purified virus like particles were separated in a 4–12% (w/v) acrylamide NuPAGE gradient pre-cast gel (LifeTechnologies). Samples were resolved for 40 min at a constant voltage of 180 V and transferred into a PVDF membrane (Merck, Billerica, Massachusetts, EUA) using a Trans-Blot® Turbo™ Transfer System (BioRad, California, USA). After transferring, PVDF membranes were blocked with 4% (w/v) skimmed milk (Merck) and incubated with the respective primary antibody: rabbit anti-CD81 (Sigma-Aldrich), mouse anti-β-Tubulin antibody (SantaCruz, CA, USA), mouse anti-HCV E1 (Acris Antibodies, Herford, Germany), mouse anti-HCV E2 (Austral Biologicals), mouse anti-HCV Core (SantaCruz) or the anti-MLV p30 monoclonal antibody produced by the hybridoma R187 (ATCC). Detection was performed with the corresponding anti-mouse or anti-rabbit secondary antibody conjugated to Horseradish peroxidase and developed using the ECL Detection Reagent (GE Healthcare, Chicago, IL USA).
To determine the presence of CD81 and HCV E2 on the cell surface 100 µL of a 1 × 106 cells/mL suspension were incubated with rabbit anti-CD81 (Sigma-Aldrich) and anti-HCV E2 (Austral Biologicals) monoclonal antibodies for 1 h, shaking at 4 °C. After extensive washing with PBS 2% (v/v) FBS, cells were incubated with Goat anti-Rabbit A594 (Thermo Scientific) and Goat anti-mouse A488 (Thermo Scientific) conjugated antibodies for an additional hour at 4 °C. At the end, cells were washed 3× with PBS 2% (v/v) FBS and the percentage of fluorescence cells was determined by flow cytometry using CYFlow space flow cytometer (Partec, Münster, Germany). Data acquisition was performed with FlowMax (Partec) software and data analysis with FlowJo v10 (FlowJo, LLC, Ashland, Ore USA).
CD81 silencing impairs HCV E2 but not HCV E1 transport to the plasma membrane
CD81-dependent transport of HCV E2 in HCV-core expressing cells
The emergence of virus-like particles (VLPs) as vaccine scaffolds enabled the development of vaccine candidates for conditions which other technologies have failed. MLV based particles were shown to efficiently incorporate HCV envelope antigens from different genotypes and to generate antibodies able to cross-neutralize all tested genotypes thus generating protective immunity (Garrone et al. 2011; Huret et al. 2013; Urbanowicz et al. 2015).
We have previously shown that host proteins present in MLV particles, such as CD81, are responsible for retroVLPs basal immunogenity (Soares et al. 2016). Since CD81 is a crucial host-factor for Hepatitis C virus, the impact of CD81 incorporation and the generation of anti-CD81 antibodies in the performance of retroVLPs based vaccines was questioned.
In 2004, Masciopinto et al. (2004) showed that hCD81 expression in CHO-cells promoted the transport of HCV envelope proteins to the plasma membrane and consequently their incorporation in exosomes. Regardless, the idea of a non-regulated process in which a small fraction of viral proteins escaping the ER retention machinery are incorporated in the plasma membrane prevails as the mechanism responsible for the incorporation of HCV envelope proteins in chimeric viral particles (Bartosch et al. 2003; Op De Beeck et al. 2004). Here we validate the transport of HCV E2 envelope protein to the plasma membrane as a regulated process dependent from cellular CD81 expression.
To further validate our observations, CD81 negative HCVpp were generated independently and produced in a clonal cell line or in a heterogeneous cell population. To enable a direct comparison between cell lines generated independently, single cell clones with similar expression of viral proteins were isolated and named 293rVLP-HCVpp and 293rVLP-HCVpp shCD81 (BEE) (Additional file 1: Figures S1 and S2). To minimize the potential amplification of unwanted characteristic underrepresented in the initial cell population during clonal selection, CD81 was de novo silenced in 293rVLP-HCVpp generating 293rVLP-HCVpp shCD81 (AEE) which was maintained as an heterogeneous cell population. A schematic representation of cell line development is shown in Fig. 1 and summarized in Additional file 1: Table S1.
The evaluation of protein expression levels in all generated cell lines indicates similar expression of HCV envelope proteins, similar silencing of CD81 and maintenance of MLV p30 expression levels (Fig. 2a). Notwithstanding similar protein expression, the levels of HCV E2 envelope protein incorporated by secreted viral particles and exposed at cell surface was consistently lower in CD81-silenced cells suggesting an inefficient transport of HCV E2 to the plasma membrane (Fig. 2b, c). The coherent reduction of surface exposed HCV E2 in HEK293 and HuH-7 cells producing HCV-LP after CD81 silencing further validates the existence of an in cis interaction between intracellular CD81 and HCV E2 responsible for HCV E2 transport to the membrane.
In contrast, CD81 silencing had no impact in the incorporation of HCV E1 on HCVpp suggesting independent transport mechanisms. The independent transport of HCV E1 grants the possibility to generate viral particles pseudotyped exclusively with HCV E1 using natural HCV sequences through cell line engineering. A chimeric HCV E1 protein enabling E1-only pseudotyping of retroVLPs, was shown to enhancing the protective potential of a vaccine candidate by increase the prevalence of rare anti-HCV E1 antibodies when administered in combination with fully pseudotyped particles in a prime-boost vaccination strategy (Garrone et al. 2011; Huret et al. 2013).
Overall, this study provides evidences that HCV envelope protein E2 transport is regulated by its intracellular association with cellular CD81. The validation of a CD81-regulated transport of HCV E2 to the plasma membrane can further contribute to elucidate understudied aspects of HCV biology such as the biogenesis of infectious HCV-genome containing exosomes present in patients’ serum. In addition, this work grants the possibility to develop HCV E1-only particles using non-engineered viral envelopes and highlights the importance of cellular host proteins for the production of functional vaccine candidates.
ASC supervised the project and revised the manuscript. HRS designed and performed experimental work, analysed the data and wrote the draft manuscript. RC and HAT participated in CD81 silencing and western blot analysis. MJTC and PMA revised the manuscript. All authors read and approved the final manuscript.
The authors also acknowledge iNOVA4Health Research Unit. H.R. Soares, R. Castro and H.A. Tomás acknowledge FCT for the individual Grants SFRH/BD/81598/2011, SFRH/BPD/72523/2010 and SFRH/BD/79022/2011 respectively.
The authors declare that they have no competing interests.
Availability of data and materials
Consent for publication
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.
This study was funded by iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), which is cofunded by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement, and also by Fundação para a Ciência e a Tecnologia, Portugal (FCT), project PTDC/BTM-SAL/30577/2017.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset F-L, Collins M, Klatzmann D (2006) DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24:2643–2655. https://doi.org/10.1016/j.vaccine.2005.11.034 CrossRefPubMedGoogle Scholar
- Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel M-P, Despres P, Tangy F, Dalba C, Klatzmann D (2009) DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 27:5772–5780. https://doi.org/10.1016/j.vaccine.2009.07.059 CrossRefPubMedGoogle Scholar
- Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset F-L, Tangy F, Klatzmann D, Bellier B (2009) Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med 11:313–325. https://doi.org/10.1002/jgm.1307 CrossRefPubMedGoogle Scholar
- Garrone P, Fluckiger A-C, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset F-L, Tangy F, Klatzmann D, Dalba C (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3:94ra71. https://doi.org/10.1126/scitranslmed.3002330 CrossRefPubMedGoogle Scholar
- Gogesch P, Schülke S, Scheurer S, Mühlebach MD, Waibler Z (2018) Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b + APC and antigen-specific T cell responses in vitro. Mol Immunol 101:19–28. https://doi.org/10.1016/j.molimm.2018.05.017 CrossRefPubMedGoogle Scholar
- Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O, Combadière B, Dalba C, Klatzmann D, Bellier B (2013) Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine 31:1540–1547. https://doi.org/10.1016/j.vaccine.2012.05.025 CrossRefPubMedGoogle Scholar
- Kirchmeier M, Fluckiger A-C, Soare C, Bozic J, Ontsouka B, Ahmed T, Diress A, Pereira L, Schodel F, Plotkin S, Dalba C, Klatzmann D, Anderson DE (2014) Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol 21:174–180. https://doi.org/10.1128/CVI.00662-13 CrossRefPubMedPubMedCentralGoogle Scholar
- Lussignol M, Kopp M, Molloy K, Vizcay-Barrena G, Fleck RA, Dorner M, Bell KL, Chait BT, Rice CM, Catanese MT (2016) Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis. Proc Natl Acad Sci 113:201518934. https://doi.org/10.1073/pnas.1518934113 CrossRefGoogle Scholar
- Rodrigues AF, Guerreiro MR, Santiago VM, Dalba C, Klatzmann D, Alves PM, Carrondo MJT, Coroadinha AS (2011) Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: tailoring vector composition. Biotechnol Bioeng 108:2623–2633. https://doi.org/10.1002/bit.23231 CrossRefPubMedGoogle Scholar
- Segura MM, Garnier A, Di Falco MR, Whissell G, Meneses-Acosta A, Arcand N, Kamen A (2008) Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J Virol 82:1107–1117. https://doi.org/10.1128/JVI.01909-07 CrossRefPubMedGoogle Scholar
- Soares HR, Castro R, Tomás HA, Rodrigues AF, Gomes-Alves P, Bellier B, Klatzmann D, Carrondo MJT, Alves PM, Coroadinha AS (2016) Tetraspanins displayed in retrovirus-derived virus-like particles and their immunogenicity. Vaccine 34:1634–1641. https://doi.org/10.1016/j.vaccine.2015.12.015 CrossRefPubMedGoogle Scholar
- Urbanowicz RA, McClure CP, Brown RJP, Tsoleridis T, Persson MAA, Krey T, Irving WL, Ball JK, Tarr AW (2015) A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. J Virol 90:3288–3301. https://doi.org/10.1128/JVI.02700-15 CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.